Comparison of liver function test- and inflammation-based prognostic scores for coronavirus disease 2019: a single center study.
Journal
European journal of gastroenterology & hepatology
ISSN: 1473-5687
Titre abrégé: Eur J Gastroenterol Hepatol
Pays: England
ID NLM: 9000874
Informations de publication
Date de publication:
01 11 2022
01 11 2022
Historique:
aheadofprint:
12
09
2022
entrez:
28
9
2022
pubmed:
29
9
2022
medline:
1
10
2022
Statut:
ppublish
Résumé
Although several liver- and inflammation-based scores to predict the clinical course of patients with coronavirus disease 2019 (COVID-19) have been evaluated, no direct comparison regarding their predictive ability has been performed. 1038 patients (608 males, age 63.5 ± 17 years) hospitalized with documented COVID-19 infection to the non-ICU ward, were included retrospectively. Clinical and laboratory characteristics on admission including evaluation of Fibrosis-4 (FIB-4) score and C-Reactive Protein (CRP) to albumin ratio (CAR) were recorded. One hundred and twenty-four patients (11.9%) died during hospitalization after 8 (3-72) days. In multivariate analysis, FIB-4 (hazard ratio, 1.11; 95% confidence interval (CI), 1.034-1.19; P = 0.004), was independently associated with mortality, with very good discriminative ability (area under the receiver operating characteristic curve curve, 0.76). The patients with FIB-4 >2.67 (n = 377), compared to those with ≤2.67 (n = 661), had worse survival (log-rank 32.6; P < 0.001). Twenty-four (6.8%) of 352 patients with possible nonalcoholic fatty liver disease (NAFLD) (defined as Hepatic Steatosis Index >36) died during hospitalization. In multivariate analysis, CAR was an independent risk factor (1) for mortality (hazard ratio, 1.014; 95% CI, 1.002-1.025; P = 0.021), (2) the need for high-flow nasal cannula with or without intubation (hazard ratio, 1.016; 95% CI, 1.004-1.027; P = 0.007) and (3) development of acute kidney injury (hazard ratio, 1.017; 95% CI, 1.006-1.028; P = 0.002). In addition, the patients with possible NAFLD and CAR >12 (n = 154), compared to those with CAR ≤12 (n = 198), had worse survival (log-rank 5.1; P = 0.024). FIB-4 was an independent factor for mortality with better performance compared to other liver function test- and inflammation-based scores in patients with COVID-19, while CAR was the only score independently associated with the clinical course in COVID-19 patients with possible NAFLD.
Sections du résumé
BACKGROUND
Although several liver- and inflammation-based scores to predict the clinical course of patients with coronavirus disease 2019 (COVID-19) have been evaluated, no direct comparison regarding their predictive ability has been performed.
METHODS
1038 patients (608 males, age 63.5 ± 17 years) hospitalized with documented COVID-19 infection to the non-ICU ward, were included retrospectively. Clinical and laboratory characteristics on admission including evaluation of Fibrosis-4 (FIB-4) score and C-Reactive Protein (CRP) to albumin ratio (CAR) were recorded.
RESULTS
One hundred and twenty-four patients (11.9%) died during hospitalization after 8 (3-72) days. In multivariate analysis, FIB-4 (hazard ratio, 1.11; 95% confidence interval (CI), 1.034-1.19; P = 0.004), was independently associated with mortality, with very good discriminative ability (area under the receiver operating characteristic curve curve, 0.76). The patients with FIB-4 >2.67 (n = 377), compared to those with ≤2.67 (n = 661), had worse survival (log-rank 32.6; P < 0.001). Twenty-four (6.8%) of 352 patients with possible nonalcoholic fatty liver disease (NAFLD) (defined as Hepatic Steatosis Index >36) died during hospitalization. In multivariate analysis, CAR was an independent risk factor (1) for mortality (hazard ratio, 1.014; 95% CI, 1.002-1.025; P = 0.021), (2) the need for high-flow nasal cannula with or without intubation (hazard ratio, 1.016; 95% CI, 1.004-1.027; P = 0.007) and (3) development of acute kidney injury (hazard ratio, 1.017; 95% CI, 1.006-1.028; P = 0.002). In addition, the patients with possible NAFLD and CAR >12 (n = 154), compared to those with CAR ≤12 (n = 198), had worse survival (log-rank 5.1; P = 0.024).
CONCLUSIONS
FIB-4 was an independent factor for mortality with better performance compared to other liver function test- and inflammation-based scores in patients with COVID-19, while CAR was the only score independently associated with the clinical course in COVID-19 patients with possible NAFLD.
Identifiants
pubmed: 36170686
doi: 10.1097/MEG.0000000000002446
pii: 00042737-202211000-00011
doi:
Substances chimiques
Albumins
0
C-Reactive Protein
9007-41-4
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1165-1171Informations de copyright
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Références
Munster VJ, Koopmans M, van Doremalen N, van Riel D, de Wit E. A novel coronavirus emerging in China - key questions for impact assessment. N Engl J Med 2020; 382:692–694.
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395:497–506.
Shirbhate E, Pandey J, Patel VK, Kamal M, Jawaid T, Gorain B, et al. Understanding the role of ACE-2 receptor in pathogenesis of COVID-19 disease: a potential approach for therapeutic intervention. Pharmacol Rep 2021; 73:1539–1550.
La Torre G, Marte M, Massetti AP, Carli SM, Romano F, Mastroianni CM, et al.; COVID-Collaborative group. The neutrophil/lymphocyte ratio as a prognostic factor in COVID-19 patients: a case-control study. Eur Rev Med Pharmacol Sci 2022; 26:1056–1064.
Li Y, Li H, Song C, Lu R, Zhao Y, Lin F, et al. Early prediction of disease progression in patients with severe COVID-19 using C-reactive protein to albumin ratio. Dis Markers. 2021; 2021:630418.
Afşin A, Tibilli H, Hoşoğlu Y, Asoğlu R, Süsenbük A, Markirt S, et al. Fibrinogen-to-albumin ratio predicts mortality in COVID-19 patients admitted to the intensive care unit. Adv Respir Med. 2021 [in press]
McGrowder DA, Miller F, Anderson Cross M, Anderson-Jackson L, Bryan S, Dilworth L. Abnormal liver biochemistry tests and acute liver injury in COVID-19 patients: current evidence and potential pathogenesis. Diseases 2021; 9:50.
Spearman CW, Aghemo A, Valenti L, Sonderup MW. COVID-19 and the liver: A 2021 update. Liver Int 2021; 41:1988–1998.
Ekpanyapong S, Bunchorntavakul C, Reddy KR. COVID-19 and the liver: lessons learnt from the EAST and the WEST, a year later. J Viral Hepat 2022; 29:4–20.
Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, et al.; APRICOT Clinical Investigators. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006; 43:1317–1325.
Davidov-Derevynko Y, Ben Yakov G, Wieder A, Segal G, Naveh L, Orlova N, et al. The liver in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Eur J Gastroenterol Hepatol 2021; 33:e313–e319.
Lin ZH, Xin YN, Dong QJ, Wang Q, Jiang XJ, Zhan SH, et al. Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis. Hepatology 2011; 53:726–736.
Johnson PJ, Berhane S, Kagebayashi C, Satomura S, Teng M, Reeves HL, et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol 2015; 33:550–558.
Lee JH, Kim D, Kim HJ, Lee CH, Yang JI, Kim W, et al. Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease. Dig Liver Dis 2010; 42:503–508.
Hanley JA, McNeil BJ. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 1983; 148:839–843.
Sterling RK, Shin D, Shin Y, French E, Stevens MP, Bajaj JS, et al. Fibrosis-4 predicts the need for mechanical ventilation in a national multiethnic cohort of coronavirus disease 2019. Hepatol Commun 2021; 5:1605–1615.
Crisan D, Avram L, Grapa C, Dragan A, Radulescu D, Crisan S, et al. Liver injury and elevated FIB-4 define a high-risk group in patients with COVID-19. J Clin Med 2021; 11:153.
Torun A, Çakirca TD, Çakirca G, Portakal RD. The value of C-reactive protein/albumin, fibrinogen/albumin, and neutrophil/lymphocyte ratios in predicting the severity of COVID-19. Rev Assoc Med Bras (1992) 2021; 67:431–436.
Karakoyun I, Colak A, Turken M, Altin Z, Arslan FD, Iyilikci V, et al. Diagnostic utility of C-reactive protein to albumin ratio as an early warning sign in hospitalized severe COVID-19 patients. Int Immunopharmacol 2021; 91:107285.
Younossi ZM, Stepanova M, Lam B, Cable R, Felix S, Jeffers T, et al. Independent predictors of mortality among patients with NAFLD hospitalized with COVID-19 infection. Hepatol Commun. 2021 [in press].
Ou M, Zhu J, Ji P, Li H, Zhong Z, Li B, et al. Risk factors of severe cases with COVID-19: a meta-analysis. Epidemiol Infect 2020; 148:e175.
Ramos-Lopez O, San-Cristobal R, Martinez-Urbistondo D, Micó V, Colmenarejo G, Villares-Fernandez P, et al. Proinflammatory and hepatic features related to morbidity and fatal outcomes in COVID-19 patients. J Clin Med 2021; 10:3112.
Weber S, Hellmuth JC, Scherer C, Muenchhoff M, Mayerle J, Gerbes AL. Liver function test abnormalities at hospital admission are associated with severe course of SARS-CoV-2 infection: a prospective cohort study. Gut 2021; 70:1925–1932.
Lombardi Y, Azoyan L, Szychowiak P, Bellamine A, Lemaitre G, Bernaux M, et al.; AP-HP/Universities/INSERM COVID-19 Research Collaboration AP-HP COVID CDR Initiative. External validation of prognostic scores for COVID-19: a multicenter cohort study of patients hospitalized in greater Paris university hospitals. Intensive Care Med 2021; 47:1426–1439.
Oikonomou T, Goulis I, Kiapidou S, Tagkou N, Akriviadis E, Papatheodoridis G, Cholongitas E. The significance of C-reactive protein to albumin ratio in patients with decompensated cirrhosis. Ann Gastroenterol 2020; 33:667–674.
Tahery N, Khodadost M, Jahani Sherafat S, Rezaei Tavirani M, Ahmadi N, Montazer F, et al. C-reactive protein as a possible marker for severity and mortality of COVID-19 infection. Gastroenterol Hepatol Bed Bench 2021; 14:S118–S122.
Wagner J, Garcia-Rodriguez V, Yu A, Dutra B, Larson S, Cash B, et al. Elevated transaminases and hypoalbuminemia in COVID-19 are prognostic factors for disease severity. Sci Rep 2021; 11:10308.
Bayram M, Yildirim O, S Ozmen R, Soylu B, Dundar AS, Koksal AR, et al. Prognostic Nutritional Index and CRP, age, platelet count, albumin level score in predicting mortality and intensive care unit admission for COVID-19. Biomark Med 2021; 15:1733–1740.